2024-11-11T14:45:50-07:00 2024-06-30 990 2023-07-01 030485196 MYELIN REPAIR FOUNDATION INC MYEL 20111 Edinburgh Drive Saratoga CA 95070 Scott Johnson Chief Executive Officer 4087610201 2024-11-11 1 2023 2024-10-15 13:58:12Z Scott Johnson 20111 Edinburgh Dr Saratoga CA 95070 266071 0 X myelinrepair.org X 2002 CA Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. Myelin Repair Foundation is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials 5 4 1 0 0 0 527737 201187 0 0 24502 52232 0 12652 552239 266071 230000 310296 0 0 138719 143278 0 0 13357 94640 50130 463359 503704 88880 -237633 1550183 1295871 623940 607261 926243 688610 Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. The MRF is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials 0 0 477938 310296 266071 We only have one area of program services and that is scientific research to benefit Multiple Sclerosis (MS) patients. Currently our research is focused on experiments to identify biomarkers to indicate repair of myelin damaged by MS. Over the last year, we focused our research on extracellular vesicles(EVs) isolated from blood. We currently have 8 investigations underway spread across Europe and North America. We have encouraging preliminary data showing that we can clearly distinguish MS patient EV's from healthy controls and may be able to identify sub-types of MS. 0 0 0 477938 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 6 0 1 1 1 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1 1 1 1 0 0 CA X Louise Savoie 4088885542 2198 Hillstone Dr San Jose CA 95138 Scott Johnson CEO 20 0 X X 120000 0 0 Andy Cates Director 1 0 X 0 0 0 Bobby Mehta Director 1 0 X 0 0 0 Jim Gidwitz Director 1 0 X 0 0 0 Eric Hsu Director 1 0 X 0 0 0 120000 0 0 1 0 0 0 0 201187 201187 0 52232 52232 0 0 0 0 0 0 0 0 0 0 0 0 0 0 12652 12652 0 0 12652 266071 64884 0 0 200296 200296 0 0 110000 110000 120000 103200 6000 10800 13664 11751 683 1230 9614 8268 481 865 4988 4988 0 37217 37217 5135 4416 257 462 2790 2790 503704 477938 12409 13357 111449 84313 1254746 1054139 168000 143000 15988 14419 1550183 1295871 623940 607261 0 623940 607261 X 926243 688610 0 0 926243 688610 1550183 1295871 -237633 0 0 0 0 0 X 0 0 0 X 253579 478580 262804 527737 201187 1723887 253579 478580 262804 527737 201187 1723887 780522 943365 11669 699 914 31061 52232 96575 51048 21709 0 12652 85409 1905871 0.49498 0.74565 X Schedule A, Part II, Line 10 Unused Scientific Research Funds RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 North America (including Canada and Mexico, but not the United States) 0 0 Program Services Investigating extracellular vesicle (EV)-derived microRNAs (miRNAs) from neurons and oligodendrocytes as biomarkers in multiple sclerosis (MS) 50000 Europe (including Iceland and Greenland) 0 0 Program Services Study of astrocyte-derived extracellular vesicles as potential prognostic biomarkers in multiple sclerosis. And development of reliable assays to isolate cell type-enriched EVs from serum as a platform for biomarker discovery in multiple sclerosis 60000 0 0 110000 North America (including Canada and Mexico, but not the United States) Scientific Research 50000 cash progress payment 0 contractual amount Europe (including Iceland and Greenland) Scientific Research 60000 Cash progress payments 0 contractual amount 2 1 0 0 0 0 0 0 Schedule F, Part I, Line 2 Grants outside of the United States are treated the same as grants within the United States with regular required reports and conversations with recipients 1 John Hopkins School of Medicine 12529 Collections Center Drive Chicago IL 60693 520595110 50296 0 contractual amount Chi separation of QSM images: A new tool to image myelin vs iron in chronic MS lesions Cornell University 575 Lexington Ave New Youk NY 10022 150532082 150000 0 contractual amount Isolation and molecular characterization of CNS-derived, cell-specific extracellular vesicles from Multiple Sclerosis blood Samples and Identify Clostridium perfringens Epsilon Toxin Specific Extracellular Vesicle Signature in MS Patients 2 0 Schedule I, Part I, Line 2 The Recipients are subject to the terms and conditions of the sponsored research agreement between them and the MRF. The researchers' work is reviewed by the MRF Scientific Director, the Executive Committee, and the MRF president Form 990, Part VI, Section A, Line 9 Andy Cates- 429N Main Street, suite 100 Memphis, TN 38103 Jim Gidwitz- 440 S LaSalle, suite 3100, Chicago, IL 60605 Bobby Mehta- 159 E. Walton Street, Chicago, IL 60611 Eric Hsu - 650 Page Mill Road. Palo Alto, CA 94304-1050 Form 990, Part VI, Section B, Line 11b Form 990 is reviewed by the CEO and once the CEO approves, it is then forwarded to the board members for their review prior to filing. board members are encouraged to review and forward their questions, if any, to the CEO Form 990, Part VI, Section B, Line 12c Officers, directors, and key employees are covered. Any and all conflicts are reviews by disinterested board members and, if needed, by legal counsel. Persons with a conflict of interest will be restricted from making any key decisions for MRF as they relate to the interest unless otherwise approved by the majority of the disinterested parties Form 990, Part VI, Section B, Line 15 Compensation is determined by the board of directors Form 990, Part VI, Section C, Line 19 Financial Statements, governing documents, and policies are available upon request for the same period of time set forth in Sec.6104(D)